Sana Biotechnology SANA Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's proceeds from exercises of stock options and other stock issuances?
- Sana Biotechnology (SANA) reported proceeds from exercises of stock options and other stock issuances of $59K in Q1 2026.
- How has Sana Biotechnology's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Sana Biotechnology's proceeds from exercises of stock options and other stock issuances decreased by 94.8% year-over-year, from $1.13M to $59K.
- What is the long-term trend for Sana Biotechnology's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), Sana Biotechnology's proceeds from exercises of stock options and other stock issuances has grown at a -14.7% compound annual growth rate (CAGR), from $4.31M to $2.68M.